View More Recent Stories
-
Citi Removes Two names from 90-Day Catalyst Watch Lists
-
Goldman Sachs Starts Tandem Diabetes Care (TNDM) at Neutral
-
RBC Capital Starts Tandem Diabetes Care (TNDM) at Outperform
-
Citi Opens 90-Day Downside Catalyst Watch on Tandem Diabetes Care (TNDM)
-
Stifel Reiterates Buy Rating on Tandem Diabetes Care (TNDM)
-
Stifel Reiterates Buy Rating on Tandem Diabetes Care (TNDM)
-
Morgan Stanley Starts Tandem Diabetes Care (TNDM) at Equalweight
-
Selloff in MedTech stocks 'seems overdone': Citi
-
Lake Street Capital Markets Reiterates Buy Rating on Tandem Diabetes Care (TNDM)
-
Canaccord Genuity Starts Tandem Diabetes Care (TNDM) at Buy
-
Tandem Diabetes Care (TNDM) PT Raised to $55 at Piper Sandler
-
Tandem Diabetes (TNDM) August 40 calls active
-
Tandem Diabetes (TNDM) Tops Q2 EPS by 7c, provides guidance
-
Tandem Diabetes (TNDM) and Dexcom (DXCM) Announce the t:slim X2 Insulin Pump with Dexcom G7 CGM Compatibility is Authorized for Sale by Health Canada
-
After-hours movers: DexCom, Skechers, Deckers Brands, and more
-
MedTech stocks: Q2 earnings season preview
-
Jefferies Reiterates Buy Rating on Tandem Diabetes Care (TNDM)
-
Tandem Diabetes (TNDM) Appoints Jean-Claude Kyrillos as COO
-
Tandem Diabetes Care (TNDM) PT Raised to $58 at Oppenheimer

